ARMS Medical & Tissue Regenix BioSurgery Sign Exclusive Distributor Agreement for DermaPure® Allograft with dCELL® Technology
27 February 2018 - 2:35AM
Business Wire
Companies collaborate to educate surgeons and
hospitals about the safety, comfort and performance advantages of
DermaPure® biologic for pelvic floor surgery
ARMS Medical, a supplier of advanced surgical technologies and
tools, and Tissue Regenix BioSurgery, an international medical
technology company, today announced they have entered into an
exclusive distributor agreement for DermaPure® dermal allograft.
The multi-year agreement gives ARMS Medical exclusive rights to
distribute the Tissue Regenix biologic to hospitals and surgeons
throughout the United States for use in urology and gynecology
procedures.
David Pennington, vice president of sales for Tissue Regenix
BioSurgery, stated, “We chose ARMS Medical as our exclusive
distributor because of their strong relationships with Key Opinion
Leaders in the urogyn space. Additionally, they are known for
bringing innovation to women’s pelvic health solutions. ARMS
Medical has helped us extend the use of DermaPure into pelvic floor
surgery which could open the opportunity for a more novel approach
compared to existing technologies. Together, we are providing
education and onboarding for surgeons with the goal of improving
patient outcomes and satisfaction.”
Rob Greer, Founder of ARMS Medical, commented “Our strong
partnership with Tissue Regenix is advancing the treatment options
for pelvic floor surgery. We believe DermaPure allograft is the
optimal solution for repairing pelvic organ prolapse and other
conditions, and it is a key component of our suite of innovative
products. This distribution agreement will empower ARMS Medical to
expand adoption of DermaPure by hospitals and surgeons for the
benefit of women.”
DermaPure results
DermaPure is a next-generation decellularized dermal allograft
processed with patented dCELL® technology. The dCELL® process
creates a bio-inductive scaffold resulting from to the removal
of DNA and cellular material from biological tissues,
DermaPure enables the patient's cells to repopulate and colonize,
creating new tissue that is recognized and accepted by the body and
stimulates a natural healing process.
According to James Lukban, DO, FACOG, FACS, FFPMRS, a
Colorado-based urogynecologic surgeon, “Since learning about
DermaPure from ARMS Medical, I have been very impressed by its
advantages over other technologies and competitive biologics. It
offers good handling characteristics, is easy to place,
incorporates well into surrounding tissue and has a negligible
exposure rate. The proprietary dCELL technology promotes tissue
growth and healing more effectively than cross-linked products. and
I continue to advocate strongly for its use in pelvic organ
prolapse and surgical repair.”
TRX BioSurgery will be exhibiting at the Society of Urodynamics,
Female Pelvic Medicine, & Urogenital Reconstruction (SUFU),
February 27 – March 3, 2018, Austin, TX.
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL®') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a
multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®,
a biotech company that specializes in regenerative medicine and is
dedicated to the development of innovative osteoinductive and wound
care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
About ARMS Medical
ARMS Medical provides advanced surgical technologies and tools
for pelvic floor issues, including organ prolapse and incontinence.
Our goal is to help patients, surgeons and hospitals by optimizing
outcomes, maximizing safety and minimizing complications. ARMS
Medical supplies a suite of products to the healthcare industry,
including DermaPure allograft, StitchKit® suturing technology,
Smoke Evacuation Pencil and Veronikis Vaginal Retractor
System™.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180226005980/en/
Tissue Regenix GroupCaitlin PearsonCorporate Communications
Director0330-430-3073orFTI ConsultingMo Noonan0203 727 1000
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024